
Kezar Life Sciences Inc (NASDAQ:KZR) shares are surging in Monday's after-hours session after the company announced topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib.
Zetomipzomib is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases.